What Allergan's Latest Developments Tell Us

1 2 3 4 5 6 7
What Allergan's Latest Developments Tell Us PART 1 OF 7

Behind Allergan’s Developments after 2Q17

A look at Allergan

Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on developing, manufacturing, and commercialization of pharmaceuticals, devices, and biologic products worldwide.

Behind Allergan’s Developments after 2Q17

Interested in AGN? Don't miss the next report.

Receive e-mail alerts for new research on AGN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

AGN’s recent developments

On September 19, 2017, Allergan’s Allure received three 2017 Best of the Beauty Breakthrough awards. The three products that were awarded include Juvederm Volbella XC, SkinMedica Lytera 2.0 Pigment Correction Serum, and Rhofade Cream 1%.

On September 12, 2017, Allergan launched the next generation of US-based Brilliant Distinctions program. The new program includes a new digital platform, and additional products like CoolSculpting, an aesthetic portfolio from Allergan, Botox Cosmetic and Juvederm, SkinMedica products, and Latisse, from the facial aesthetics portfolio.

Other developments

On September 8, 2017, Allergan and Saint Regis Mohawk Tribe announced that the Orange Book-listed patents for Restasis are owned by Tribe, while Allergan holds the licenses to these patents related to Restasis.

On September 6, 2017, Allergan announced that the company will release new data on chronic migraine at the International Headache Congress 2017 in Vancouver. On August 28, 2017, Allergan announced the settlement its patent litigation with FamyCare for Restasis 0.05%. These patents are listed in the Orange Book and are valid up to August 27, 2024.

On July 27, 2017, Allergan’s drug Truberzi (eluxadoline) received a positive recommendation from NICE (National Institute of Health and Care Excellence) for the treatment of adults with irritable bowel syndrome with diarrhea. Truberzi is a twice-daily oral medication for the treatment of bloating, diarrhea, pain, and urgency in patients with irritable bowel syndrome with diarrhea.

Notably, the Health Care Select Sector SPDR ETF (XLV) has 2.6% of its total assets in Allergan. XLV also holds 5.6% in Merck (MRK), 6.4% in Pfizer (PFE), and 3.3% in Bristol-Myers Squibb (BMY).


Please select a profession that best describes you: